All In Biotech

Drug Trial Radar · NCT00301236

Efficacy, Tolerability and Safety of Dexmethylphenidate HCl Extended-Release Capsules in Children With Attention-Deficit/Hyperactivity Disorder

A 5-Week Treatment, Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Fixed-Dose Study of the Efficacy, Tolerability and Safety of Dexmethylphenidate HCl Extended-Release Capsules Administered Once Daily in Pediatric Children With Attention-Deficit/Hyperactivity Disorder

Last checked: Nov 19, 2026Latest source record: Dec 21, 2007 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 252 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

252

Actual

Start

Feb 2006

Primary completion

Not stated

Study completion Nov 2006

Sponsor

Lead sponsor
NovartisNovartis (NVS)
Sponsor type
Industry
First posted
Mar 10, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 6 years, up to 12 years

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine which dosages of dexmethylphenidate HCl extended-release capsules may represent effective treatment for ADHD in children 6-12 years of age.

Conditions

  • ADHD, ADD

Interventions

  • Dexmethylphenidate HCl extended-release capsulesDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Assessment of the symptoms by the patient's teacher after 5 weeks of treatment.

Locations

25 sites in 1 country. Site status is shown where the registry gives one.

  • Novartis Investigational Site

    Mesa, Arizona

  • Novartis Investigational Site

    Little Rock, Arkansas

  • Novartis Investigational Site

    Los Angeles, California

  • Novartis Investigational Site

    Boulder, Colorado

  • Novartis Investigational Site

    Maitland, Florida

  • Novartis Investigational Site

    Orlando, Florida

  • Novartis Investigational Site

    Stone Mountain, Georgia

  • Novartis Investigational Site

    Libertyville, Illinois

  • Novartis Investigational Site

    Overland Park, Kansas

  • Novartis Investigational Site

    Prairie Village, Kansas

  • Novartis Investigational Site

    Cambridge, Massachusetts

  • Novartis Investigational Site

    Las Vegas, Nevada

  • Novartis Investigational Site

    Piscataway, New Jersey

  • Novartis Investigational Site

    Toms River, New Jersey

  • Novartis Investigational Site

    New York, New York

  • Novartis Investigational Site

    New York, New York

  • Novartis Investigational Site

    Staten Island, New York

  • Novartis Investigational Site

    Chapel Hill, North Carolina

  • Novartis Investigational Site

    Raleigh, North Carolina

  • Novartis Investigational Site

    Columbus, Ohio

  • Novartis Investigational Site

    Gresham, Oregon

  • Novartis Investigational Site

    Philadelphia, Pennsylvania

  • Novartis Investigational Site

    Jackson, Tennessee

  • Novartis Investigational Site

    Memphis, Tennessee

  • Novartis Investigational Site

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.